Virtici, LLC

SEATTLE, WA 98122

SBIR Award Summary

Total Number of Awards 11
Total Value of Awards $4.93MM
Active Awards 3 valued at $825K
First Award Date 05/15/14
Most Recent Award Date 09/15/17

3 Active Awards Valued at $825K

Award Title Awarding Agency Phase Award amount Start Date End Date
A Novel Tolerance Therapeutic for Treating Type 1 Diabetes HHS 1 $300K 09/15/17 08/31/18
A Novel Tolerance-inducing Probiotic Platform HHS 1 $300K 08/02/17 07/31/18
A Novel Probiotic for the Treatment of Rheumatoid Arthritis HHS 1 $225K 08/01/17 07/31/18

Key Personnel

Last Name Name Awards Contact
FANGER NEIL A FANGER 11

11 Awards Won

Phase 1 SBIR Active

Agency: Department of Health & Human Services
Topic: PA-16-302
Budget: 09/15/17 - 08/31/18

Project Summary Our goal is to develop VTC-D87 as a novel tolerance-inducing therapeutic for the treatment of Type 1 Diabetes (T1D). T1D is an autoimmune disease characterized by the destruction of the insulin-producing pancreatic beta cells11, 12. While the etiology of T1D remains undefined, evidence suggests that autoimmunity to insulin is a m...

Phase 1 SBIR Active

Agency: Department of Health & Human Services
Topic: PA-16-302
Budget: 08/02/17 - 07/31/18

Project Summary Our goal is to validate a novel Lactococcus lactis (L. lactis)-based platform to rapidly develop and deliver tolerance-inducing therapeutics for the treatment of autoimmunity and allergy. Autoimmune and allergic diseases, such as Multiple Sclerosis (MS), Type 1 Diabetes, and food allergies affect 25-50% of the world population, a...

Phase 1 SBIR Active

Agency: Department of Health & Human Services
Topic: PA-16-302
Budget: 08/01/17 - 07/31/18

Project Summary Our goal is to develop a novel L. lactis probiotic-based therapeutic for the treatment of rheumatoid arthritis (RA). RA is a chronic, systemic inflammatory disorder affecting as much as 0.24% worldwide, and as much as 1% of the US population12, 13. The exact frequencies depend on geographical origin and gender, women being three ...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-16-302
Budget: 05/05/17 - 04/30/18

Project Summary The goal of this project is to develop a novel peptide therapeutic, VTC-G15, for the treatment of obesity. Today, one-third of adults in the United States (US) are obese, with an estimated annual healthcare burden of approximately $150 billion40. By 2030, it is projected that over 50% of adults in the US will be obese with a year...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-15-269
Budget: 04/24/17 - 03/31/18

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-15-269
Budget: 08/02/16 - 07/31/17

Project SummaryOur goal is to develop a novel L. lactis probiotic-based therapeutic for the treatment of Sjögren's Syndrome(SjS). SjS is a progressive, chronic autoimmune disease characterized by inflammatory cell infiltration of thesalivary and lacrimal glands, resulting in acinar epithelial cell atrophy, cell death, and loss of exocrine functi...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-15-269
Budget: 04/15/16 - 03/31/17

? DESCRIPTION (provided by applicant): Our goal is to develop VTC-MS3 as a novel tolerance-inducing therapeutic to treat Multiple Sclerosis (MS). MS is the most common demyelinating disorder of the Central Nervous System (CNS), affecting approximately 2.3 million people worldwide and 400,000 in the US alone28, 29. Current and developing treat...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 09/30/15 - 09/29/16

DESCRIPTION (provided by applicant): Our goal is to develop a novel peptide therapeutic to alleviate brain and vascular injury after hemorrhagic and ischemic stroke. Vascular injury is a leading cause of death in the United States, with approximately 795,000 Americans suffering stroke, with 137,000 deaths each year [1]. Those who survive are fre...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 03/01/15 - 02/29/16

DESCRIPTION (provided by applicant): Our goal is to develop VTC-064 as a novel tolerance-inducing therapeutic to treat peanut allergy. Peanut allergy is one of the most common and potentially fatal forms of food allergy, affecting nearly three million Americans1. Unlike many food allergens, approximately 80% of individuals allergic to peanuts r...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-13-234
Budget: 09/01/14 - 08/31/15

DESCRIPTION (provided by applicant): The goal of this project is to develop a novel peptide therapeutic, GLP-1-5, for the treatment of obesity. Today, one-third of adults in the United States (US) are obese, with an estimated annual healthcare burden of approximately $150 billion. By 2030, it is projected that over 50% of adults in the US will b...

Load More